Study Condition(s): Soft Tissue Sarcoma

A Study of Olaratumab (LY3012207) Plus Pembrolizumab in Participants With Advanced or Metastatic Soft Tissue Sarcoma

Study Alias: JGDQ

Study Identifier(s): Tool Tip Icon {{ defaultRegistry.registryAnchorText }} NCT03126591 {{ currentLocaleObject.registryAnchorText }}

Study Purpose

The purpose of this study is to evaluate the safety of olaratumab plus pembrolizumab in participants with previously treated advanced or metastatic soft tissue sarcoma.

Key Participation Requirements Tool Tip Icon

All clinical trials have rules about who can participate. This section outlines some of those rules. Please contact a study center to discuss the full set of criteria

Gender

Male Female

Age

18+ years

Time Commitment

The duration of your participation depends on how well your disease responds to the study treatment.
  • Participant must have a diagnosis of advanced unresectable or metastatic soft tissue sarcoma confirmed by histology
  • Participant must be able to provide tumor tissue obtained within 6 months of enrolling in the study (if no such tissue is available, must be willing to provide a core or excisional biopsy)
  • Participant must have an anticipated life expectancy of 3 months or more
  • Participant must not have active autoimmune disease or any other syndrome that require systemic steroids or autoimmune agents in the past 2 years
  • Participant must not have received a live-virus vaccine within 30 days of planned treatment
  • Participant must not have inflammatory bowel disease for which immunosuppressive agents were used in the last 2 years

Where to Participate

6 locations are currently available of 6 planned
Invalid Postal Code.
Please re-enter postal code.

{{sites.getPageStartCount()}} - {{sites.getPageEndCount()}} of {{sites.totalCount}} Results

0 of {{sites.totalCount}} Results

Distance Location Status
{{site.getDistance() | number:0}} {{convertUnit("imperial", "mile") | translate}} {{convertUnit("imperial", "miles") | translate}}
,
Status {{site.siteStatus}} {{site.siteStatus}} {{site.siteStatus}} {{site.siteStatus}} {{site.siteStatus}} {{site.siteStatus}} {{site.siteStatus | translate}}
Closest Location to Participate
{{site.getDistance() | number:0}} {{convertUnit("imperial", "mile") | translate}} {{convertUnit("imperial", "miles") | translate}}
,
Status {{site.siteStatus}} {{site.siteStatus}} {{site.siteStatus}} {{site.siteStatus}} {{site.siteStatus}} {{site.siteStatus}} {{site.siteStatus | translate}}
Other Location(s) to Participate
{{site.getDistance() | number:0}} {{convertUnit("imperial", "mile") | translate}} {{convertUnit("imperial", "miles") | translate}}
,
Status {{site.siteStatus}} {{site.siteStatus}} {{site.siteStatus}} {{site.siteStatus}} {{site.siteStatus}} {{site.siteStatus}} {{site.siteStatus | translate}} {{site.getSiteCTALabel() | translate}}

To improve your experience on Lilly TrialGuide, please use the latest version of Chrome, Firefox, Safari, or Internet Explorer, with Java Script enabled.
This website is not optimized for your browser, as configured.